Invests in healthcare-related real estate assets. Manages a portfolio of medical office buildings. Now — the numbers.
This is an established company with proven profits.
Average growth of 16% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 158.7× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 27% of them.
Analysts' average target sits 20% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Growth: Sales growth trails the sector average.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 16% a year on average.
It pays out $1.00 per share each year — regular cash for whoever holds the stock.
The company’s market value is 159 times its annual profit. Even a small disappointment could hit the price hard.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 27/100.
The growth engine is running at low revs right now. Report-card grade: 35/100.
On our five-subject report card, AHR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AHR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (27/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.